REVMATOID ARTRIT BILAN OGʻRIGAN BEMORLARDA SURUNKALI BUYRAK KASALLIKNING RIOVLANISH XAVF OMILLAR, KASALLIKNING TARQALGANLIGI VA BUYRAKLAR ZARARLANISH VARIANTLAR
Дата публикации: 10 May 2025
Участники
Gulasalxon Jurayeva
Author
DOI
Ключевые слова
revmatoid artrit
surunkali buyrak kasalligi
amioldoiz
mezangial glomerulonefrit
IgA glomerulonefrit
koptokchalar filtratsiya tezligi
nefropatiya
nostreoid yaligʻllanishga qarshi preparatlar
metatreksat.
Сборник материалов
Трек
General Track
Аннотация
Revmatoid artrit (RA) -keng tarqalgan kasallik boʻlib, uning buyraklar bilan bogʻliq muammolari nisbatan tez-tez uchraydi va bu asosiy kasallikning davomiyligi va oʻlimini yomonlashtiradi .Revmatoid artrit (RA) – surunkali autoimmun yalligʻlanish kasalligi boʻlib, u nafaqat boʻgʻimlarga, balki ichki organlarga, masalan, buyraklarga ham taʼsir koʻrsatadi. RA bilan bogʻliq buyrak shikastlanishi surunkali buyrak kasalligi (SBK) rivojlanish xavfini oshiradi. Maskur maqolada RA bilan bogʻliq buyrak zararlanishining , asosiy xavf omillari,patogenezi, klinik koʻrinishlari koʻrib chiqiladi. Shuningdek, zamonaviy davolash yondashuvlari bilan tanishiladi. RA va buyrak shikastlanishi boʻlgan bemorlarning biopsiya namunalaridagi gistoimmunologik tadqiqotlar, eng koʻp uchraydigan patologiyalarni aniqlashga yordam berdi.. RAda buyrak shikastlanishi ikkilamchi amiloidoz, nostriod yalligʻlanishga qarshi dorilarning nefrotoksik taʼsiri turadi. Yana koʻp uchraydigan buyrak shikstlanishi buyrak amilodoiz hisoblanadi va kasalligini kuchayishiga olib kelibi va RAda surunkali buyrak kasalligining sababi hisoblanadi.. Ushbu izohda biz NYaQP va baʼzi dori vositalarning nefrotoksikligini, ayniqsa oltin birikmalari, D-penitsillamin, siklosporin A taʼsirlarini noʻjoya taʼsirlarni koʻrib chiqamiz. Leflunomid va TNF bloklovchi retseptor (etanercept) bilan immunosuprussiv davolashda IgA glomerulonefriti bilan bogʻliq kam uchraydigan holatlar keltirilgan.
Источники
1. Boers M, Croonen AM, Dijkmans BA, et al. Renal findings in rheuma toid arthritis: clinical aspects of 132 necropsies. Ann Rheum Dis. 1987;46:658-63.
2. Батюшин М.М., Выставкина Е.А. Факторы риска развития и про- грессирования хронической болезни почек у больных ревматоид- ным артритом. Современные проблемы науки и образования. 2011;5 [Batyushin MM, Vyshkina EA. Risk factors for the development and progression of chronic kidney disease in patients with rheumatoid arthritis. Modern problems of science and education. 2011; 5 (In Russ.)]. URL: http://www.science-education.ru/ru/article/view?id=4871
3. Etiology and pathogenesis of rheumatoid arthritis. In: Firestein GS, Kel ley WN (eds). Kelleyʼs Textbook of Rheumatology, 8th edn. Philadelphia, PA: Saunders/Elsevier, 2009:1035-86.
4. Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford). 2008;47(12):1780-4.
5. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα in hibitors and rituximab. Ann Rheum Dis. 2015;74:415-21.
6. Hickson LJ, CrowsonCS, Gabriel SE, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63:206-13.
7. Foster MC, Rawlings AM, Marrett E, et al. Potential effects of reclassifying CKD as a coronary heart disease risk equivalent in the US population. Am J Kidney Dis. 2014;63:753-60.
8. Hickson LJ, Crowson CS, Gabriel SE, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63:206.
9. Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonste roidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005 Mar;45(3):531-9. doi: 10.1053/j.ajkd.2004.12.005
10. Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. J Amer Med Association. 2010;303(5):423-9.
11. Nakahara C, Kanemoto K, Saito N, Oyake Y, Kamoda T, Nagata M, et al. C-reactive protein frequently localizes in the kidney in glomerular diseases. Clin Nephrol. 2001
12. Karie S, Gandjbakhch F, Janus N, Launay-Vacher V, Rozenberg S, Mai Ba CU, Bourgeois P, Deray G. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford).
13. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т., Мартынов А.И., ЯхноI Н.Н., Арутюнов Г.П., Алексеева Л.И., Абузарова Г.Р., ЕвсеевI М.А., Кукушкин М.Л., Копенкин С.С., Лила А.М., ЛапинаIТ.Л., Новикова Д.С., Попкова Т.В., Ребров А.П., Скоробога- тых К.В., Чичасова Н.В. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология.
14. Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y. Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis. PLOS ONE. 2016. doi: 10.1371/journal.pone.016022
15. Kim HW, Lee CK, Cha HS, Choe JY, Park EJ, Kim J. Effect of antitumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease. Rheumatol Int. 2015;35(4):727-34. doi: 10.1007/s00296-014-3146-4
16. Киселева А.Г., Орлова Г.М., Бердникова И.А., Фереферова Н.М. Хроническая болезнь почек у больных ревматоидным артритом. Сибирский медицинский журнал. 2007;7:90-2 [Kiseleva AG, Orlova GM, Berdnikova IA, Ferreferova NM. Chronic kidney disease in patients with rheumatoid arthritis. Siberian Medical Journal. 2007;7:90-2 (In Russ.)]. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т., Мартынов А.И., ЯхноI Н.Н., Арутюнов Г.П., Алексеева Л.И., Абузарова Г.Р., ЕвсеевI М.А., Кукушкин М.Л., Копенкин С.С., Лила А.М., ЛапинаIТ.Л., Новикова Д.С., Попкова Т.В., Ребров А.П., Скоробогатых К.В., Чичасова Н.В. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56:1
17. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74:415-21.
18. Li Z, Chung ACK, Zhou L, Huang XR, Liu F, Fu P, et al. C-reactive protein promotes acute renal inflammation and fibrosis in unilateral ureteral obstructive nephropathy in mice. Laboratory Investigation [Article]. 2011;91(6):837-51. doi: 10.1038/labinvest.2011.42
19. Möller B, Pruijm M, Adler S, Scherer A, Villiger PM, Finckh A. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheumatic Disease. 2013:74. http://dx.doi. org/10.1136/ annrheumdis-2013-204078
20. Насонов Е.Л. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-
21. Nasonov EL. Pharmacotherapy of rheumatoid arthritis: a new strategy, new targets. Rheumatology Science and Practice. 2017;55(4):409-19 (In Russ.)]. https://doi.org/10.14412/1995-4484-2017-409-419
22. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375 (26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13
23. Оранский С.П. Хроническая болезнь почек при ревматоидно артрите: ассоциация с сердечно-сосудистым риском. Фундаментальные исследования. 2013;12(2):285-8 [Oransky SP. Chronic kidney disease in rheumatoid arthritis: an association with cardiovascular risk. Basic research. 2013;12(2):285-8 (In Russ)].
24. Toblli JE, Bevione P, Di Gennaro F, Madalena L, Cao G, Angerosa M. Understanding the mechanisms of proteinuria: therapeutic implications. Int J Nephrol. 2012:546039. doi: 10.1155/2012/546039
25. Tokoroyama T, Ando M, Setoguchi K, Tsuchiya K, Nitta K. Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a large retrospective cohort study of rheumatoid arthritis patients. Nephrol Dial Transplant. 2016;0:1-8. doi: 10.1093/ndt/gfw315
26. Ребров А.П., Тяпкина М.А., Волошинова Е. В. Субклиническое поражение почек у пациентов с ревматоидным артритом. Лечащий врач. 2012;4:40-2 [Rebrov AP, Tyapkina MA, Voloshinova EV. Subclinical kidney damage in patients with rheumatoid arthritis. Lechaschi Vrach. 2012;4:40-2 (In Russ.)].
27. Chiu HY, Huang HL, Li CH, Chen HA, Yeh CL, Chiu SH, Lin WC, Cheng YP, Tsai TF, Ho SY. Increased Risk of Chronic Kidney Disease in Rheumatoid Arthritis Associated with Cardiovascular Complications A National Population-Based Cohort Study. PLoS One. 2015;25,10(9):e0136508. doi: 10.1371/journal.pone.0136 508
28. Cannon C, Curtis S, FitzGerald G, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771-81. doi: 10.1016/S0140-6736(06)69666-9 Н.В. Чеботарева и соавт. 132 ТЕРАПЕВТИЧЕСКИЙ АРХИВ 5, 2019ХБП у больных РА
29. Shankar A, Sun L, Klein BE, Lee KE, Muntner P, Nieto FJ, et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 2011;80(11):1231-8. doi: 10.1038/ki. 2011.283
30. Schwedler SB, Guderian F, Dämmrich J, Potempa LA, Wanner C. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant. 2003;18(11):2300-7.
Загрузки
Как цитировать
Gulasalxon, G. (2025). REVMATOID ARTRIT BILAN OGʻRIGAN BEMORLARDA SURUNKALI BUYRAK KASALLIKNING RIOVLANISH XAVF OMILLAR, KASALLIKNING TARQALGANLIGI VA BUYRAKLAR ZARARLANISH VARIANTLAR. “Yangi Davr Ilm-Fani: Inson Uchun Innovatsion gʻoya Va yechimlar” Mavzusidagi Respublika Ilmiy-Amaliy Konferensiyasi, 1(1), 113-121. https://doi.org/10.47390/spro/i-res-konf-2025-26